Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF1001 in Advanced Solid Tumors
NCT04143711Phase 2Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Nov 2019
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of DF1001 in solid tumor, non-small cell lung cancer (NSCLC), breast cancer and 3 more (22 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Dose Limiting Toxicities at 3 weeks, Overall Response Rate at 1 year and 1 more. Started Nov 2019; status: completed.
02
Drugs
DF1001
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancerUrothelial Bladder Cancer (UBC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT04143711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143711.